Accelerate Stock Based Compensation from 2010 to 2024

AXDX Stock

USD 1.07 0.03 2.73%

Accelerate Diagnostics Stock Based Compensation yearly trend continues to be fairly stable with very little volatility. Stock Based Compensation is likely to outpace its year average in 2024. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2011-09-30

Previous Quarter

966 K

Current Value

1.2 M

Quarterly Volatility

13.3 M

Yuan Drop

Covid

Check Accelerate Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Accelerate Diagnostics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.4 M, Interest Expense of 8.1 M or Selling General Administrative of 35.9 M, as well as many indicators such as Price To Sales Ratio of 3.85, Dividend Yield of 2.0E-4 or Days Sales Outstanding of 75.39. Accelerate financial statements analysis is a perfect complement when working with Accelerate Diagnostics Valuation or Volatility modules.

Check out the analysis of Accelerate Diagnostics Correlation against competitors.

For more information on how to buy Accelerate Stock please use our How to Invest in Accelerate Diagnostics guide.

Latest Accelerate Diagnostics' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Accelerate Diagnostics over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Accelerate Diagnostics' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Accelerate Diagnostics' overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Accelerate Stock Based Compensation Regression Statistics

	Arithmetic Mean	9,143,517
	Coefficient Of Variation	69.66
	Mean Deviation	4,907,216
	Median	9,624,000
	Standard Deviation	6,369,769
	Sample Variance	40.6T
	Range	22.1M
	R-Value	0.65
	Mean Square Error	25.3T
	R-Squared	0.42
	Significance	0.01
	Slope	925,053
	Total Sum of Squares	568T

Accelerate Stock Based Compensation History

	2024	10 M
	2023	5.4 M
	2022	10.6 M
	2021	22 M
	2020	16.5 M
	2019	12.6 M
	2018	14.7 M

Other Fundumenentals of Accelerate Diagnostics

Stock Based Compensation To Revenue

Accelerate Diagnostics Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Treasury Stock	Property Plant Equipment	Intangible Assets	Good Will	Short Term Debt	Net Tangible Assets	Long Term Debt	Short Term Investments	Capital Surpluse	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.43	0.08	-0.21	0.14	0.25	0.51	1.0	-0.57	-0.1	-0.32	0.5	-0.47	-0.54	-0.06	0.4	0.51	0.81	0.35	0.66	-0.05	0.42	0.37	0.17
Total Stockholder Equity	0.43		-0.82	0.55	-0.18	-0.51	-0.55	0.47	-0.12	-0.25	0.66	-0.27	-0.09	-0.13	-0.25	1.0	-0.52	0.4	-0.39	-0.05	-0.22	0.55	0.56	-0.01
Net Debt	0.08	-0.82		-0.66	0.14	0.69	0.84	0.03	-0.14	0.23	-0.83	0.5	-0.11	-0.09	0.19	-0.83	0.82	0.2	0.56	0.4	0.16	-0.27	-0.3	0.1
Retained Earnings	-0.21	0.55	-0.66		-0.8	-0.86	-0.66	-0.16	0.52	-0.69	0.9	-0.93	0.44	0.47	-0.39	0.58	-0.59	-0.07	-0.98	-0.74	-0.35	0.72	0.74	0.11
Accounts Payable	0.14	-0.18	0.14	-0.8		0.65	0.21	0.11	-0.55	0.75	-0.56	0.81	-0.45	-0.47	0.45	-0.21	0.12	-0.13	0.83	0.57	0.42	-0.76	-0.79	-0.25
Net Receivables	0.25	-0.51	0.69	-0.86	0.65		0.66	0.21	-0.31	0.66	-0.85	0.82	-0.29	-0.33	0.29	-0.53	0.62	0.19	0.84	0.62	0.26	-0.5	-0.53	-0.11
Total Liab	0.51	-0.55	0.84	-0.66	0.21	0.66		0.47	-0.38	0.05	-0.89	0.65	-0.32	-0.34	0.2	-0.57	0.95	0.38	0.62	0.62	0.18	-0.07	-0.14	0.25
Total Current Assets	1.0	0.47	0.03	-0.16	0.11	0.21	0.47		-0.56	-0.12	-0.28	0.46	-0.47	-0.52	-0.08	0.45	0.47	0.82	0.31	0.63	-0.07	0.45	0.4	0.16
Common Stock	-0.57	-0.12	-0.14	0.52	-0.55	-0.31	-0.38	-0.56		-0.3	0.42	-0.68	0.64	0.46	-0.14	-0.1	-0.34	-0.39	-0.62	-0.64	-0.13	0.21	0.23	0.02
Current Deferred Revenue	-0.1	-0.25	0.23	-0.69	0.75	0.66	0.05	-0.12	-0.3		-0.41	0.61	-0.3	-0.17	0.09	-0.27	0.08	-0.09	0.71	0.43	0.06	-0.76	-0.67	-0.57
Treasury Stock	-0.32	0.66	-0.83	0.9	-0.56	-0.85	-0.89	-0.28	0.42	-0.41		-0.84	0.36	0.38	-0.34	0.68	-0.83	-0.18	-0.85	-0.66	-0.31	0.44	0.49	-0.03
Property Plant Equipment	0.5	-0.27	0.5	-0.93	0.81	0.82	0.65	0.46	-0.68	0.61	-0.84		-0.56	-0.58	0.27	-0.31	0.61	0.28	0.98	0.86	0.25	-0.53	-0.54	-0.15
Intangible Assets	-0.47	-0.09	-0.11	0.44	-0.45	-0.29	-0.32	-0.47	0.64	-0.3	0.36	-0.56		0.56	-0.12	-0.05	-0.29	-0.31	-0.52	-0.53	-0.11	0.18	0.2	0.02
Good Will	-0.54	-0.13	-0.09	0.47	-0.47	-0.33	-0.34	-0.52	0.46	-0.17	0.38	-0.58	0.56		-0.13	-0.07	-0.3	-0.33	-0.54	-0.56	-0.11	0.19	0.2	0.02
Short Term Debt	-0.06	-0.25	0.19	-0.39	0.45	0.29	0.2	-0.08	-0.14	0.09	-0.34	0.27	-0.12	-0.13		-0.26	-0.09	-0.14	0.32	0.16	1.0	-0.35	-0.6	0.62
Net Tangible Assets	0.4	1.0	-0.83	0.58	-0.21	-0.53	-0.57	0.45	-0.1	-0.27	0.68	-0.31	-0.05	-0.07	-0.26		-0.54	0.38	-0.42	-0.08	-0.23	0.57	0.58	-0.01
Long Term Debt	0.51	-0.52	0.82	-0.59	0.12	0.62	0.95	0.47	-0.34	0.08	-0.83	0.61	-0.29	-0.3	-0.09	-0.54		0.4	0.57	0.58	-0.11	-0.02	-0.01	0.02
Short Term Investments	0.81	0.4	0.2	-0.07	-0.13	0.19	0.38	0.82	-0.39	-0.09	-0.18	0.28	-0.31	-0.33	-0.14	0.38	0.4		0.19	0.51	-0.13	0.54	0.5	0.14
Capital Surpluse	0.35	-0.39	0.56	-0.98	0.83	0.84	0.62	0.31	-0.62	0.71	-0.85	0.98	-0.52	-0.54	0.32	-0.42	0.57	0.19		0.82	0.29	-0.66	-0.67	-0.16
Long Term Debt Total	0.66	-0.05	0.4	-0.74	0.57	0.62	0.62	0.63	-0.64	0.43	-0.66	0.86	-0.53	-0.56	0.16	-0.08	0.58	0.51	0.82		0.14	-0.29	-0.3	-0.05
Short Long Term Debt	-0.05	-0.22	0.16	-0.35	0.42	0.26	0.18	-0.07	-0.13	0.06	-0.31	0.25	-0.11	-0.11	1.0	-0.23	-0.11	-0.13	0.29	0.14		-0.31	-0.57	0.64
Net Invested Capital	0.42	0.55	-0.27	0.72	-0.76	-0.5	-0.07	0.45	0.21	-0.76	0.44	-0.53	0.18	0.19	-0.35	0.57	-0.02	0.54	-0.66	-0.29	-0.31		0.96	0.31
Net Working Capital	0.37	0.56	-0.3	0.74	-0.79	-0.53	-0.14	0.4	0.23	-0.67	0.49	-0.54	0.2	0.2	-0.6	0.58	-0.01	0.5	-0.67	-0.3	-0.57	0.96		0.08
Capital Stock	0.17	-0.01	0.1	0.11	-0.25	-0.11	0.25	0.16	0.02	-0.57	-0.03	-0.15	0.02	0.02	0.62	-0.01	0.02	0.14	-0.16	-0.05	0.64	0.31	0.08

Click cells to compare fundamentals

About Accelerate Diagnostics Financial Statements

Accelerate Diagnostics investors use historical fundamental indicators, such as Accelerate Diagnostics' Stock Based Compensation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Accelerate Diagnostics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Stock Based Compensation	5.4 M	10 M
Stock Based Compensation To Revenue	0.45	0.42

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Accelerate Stock Analysis

When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Accelerate Stock Based Compensation from 2010 to 2024

Latest Accelerate Diagnostics' Stock Based Compensation Growth Pattern

Accelerate Stock Based Compensation Regression Statistics

Accelerate Stock Based Compensation History

Other Fundumenentals of Accelerate Diagnostics

Accelerate Diagnostics Stock Based Compensation component correlations

About Accelerate Diagnostics Financial Statements

Also Currently Popular

Additional Tools for Accelerate Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY